B Lebwohl1,2, P H R Green1, R M Genta3,4. 1. Department of Medicine, Coeliac Disease Center, Columbia University College of Physicians and Surgeons, New York, NY, USA. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. 3. Miraca Life Sciences, Irving, TX, USA. 4. Departments of Pathology and Medicine (Gastroenterology), UT Southwestern Medical Center, Dallas, TX, USA.
Abstract
BACKGROUND: Lymphocytic gastritis (LG) is an uncommon entity with varying symptoms and endoscopic appearances. This condition, as well as two forms of H. pylori-negative gastritis [chronic active gastritis (CAG) and chronic inactive gastritis (CIG)], appears to be more common in patients with coeliac disease (CD) based on single-centred studies. AIM: To compare the prevalence of LG, CAG and CIG among those with normal duodenal histology (or nonspecific duodenitis) and those with CD, as defined by villous atrophy (Marsh 3). METHODS: We analysed all concurrent gastric and duodenal biopsy specimens submitted to a national pathology laboratory during a 6-year period. We performed multiple logistic regression to identify independent predictors of each gastritis subtype. RESULTS: Among patients who underwent concurrent gastric and duodenal biopsy (n = 287,503), the mean age was 52 and the majority (67%) were female. Compared to patients with normal duodenal histology, LG was more common in partial villous atrophy (OR: 37.66; 95% CI: 30.16-47.03), and subtotal/total villous atrophy (OR: 78.57; 95% CI: 65.37-94.44). CD was also more common in CAG (OR for partial villous atrophy 1.93; 95% CI: 1.49-2.51, OR for subtotal/total villous atrophy 2.42; 95% CI: 1.90-3.09) and was similarly associated with CIG (OR for partial villous atrophy 2.04; 95% CI: 1.76-2.35, OR for subtotal/total villous atrophy 2.96; 95% CI: 2.60-3.38). CONCLUSIONS: Lymphocytic gastritis is strongly associated with coeliac disease, with increasing prevalence correlating with more advanced villous atrophy. Chronic active gastritis and chronic inactive gastritis are also significantly associated with coeliac disease. Future research should measure the natural history of these conditions after treatment with a gluten-free diet.
BACKGROUND:Lymphocytic gastritis (LG) is an uncommon entity with varying symptoms and endoscopic appearances. This condition, as well as two forms of H. pylori-negative gastritis [chronic active gastritis (CAG) and chronic inactive gastritis (CIG)], appears to be more common in patients with coeliac disease (CD) based on single-centred studies. AIM: To compare the prevalence of LG, CAG and CIG among those with normal duodenal histology (or nonspecific duodenitis) and those with CD, as defined by villous atrophy (Marsh 3). METHODS: We analysed all concurrent gastric and duodenal biopsy specimens submitted to a national pathology laboratory during a 6-year period. We performed multiple logistic regression to identify independent predictors of each gastritis subtype. RESULTS: Among patients who underwent concurrent gastric and duodenal biopsy (n = 287,503), the mean age was 52 and the majority (67%) were female. Compared to patients with normal duodenal histology, LG was more common in partial villous atrophy (OR: 37.66; 95% CI: 30.16-47.03), and subtotal/total villous atrophy (OR: 78.57; 95% CI: 65.37-94.44). CD was also more common in CAG (OR for partial villous atrophy 1.93; 95% CI: 1.49-2.51, OR for subtotal/total villous atrophy 2.42; 95% CI: 1.90-3.09) and was similarly associated with CIG (OR for partial villous atrophy 2.04; 95% CI: 1.76-2.35, OR for subtotal/total villous atrophy 2.96; 95% CI: 2.60-3.38). CONCLUSIONS:Lymphocytic gastritis is strongly associated with coeliac disease, with increasing prevalence correlating with more advanced villous atrophy. Chronic active gastritis and chronic inactive gastritis are also significantly associated with coeliac disease. Future research should measure the natural history of these conditions after treatment with a gluten-free diet.
Authors: Alberto Rubio-Tapia; Margot L Herman; Jonas F Ludvigsson; Darlene G Kelly; Thomas F Mangan; Tsung-Teh Wu; Joseph A Murray Journal: Mayo Clin Proc Date: 2012-06-22 Impact factor: 7.616
Authors: Lars C Stene; Margo C Honeyman; Edward J Hoffenberg; Joel E Haas; Ronald J Sokol; Lisa Emery; Iman Taki; Jill M Norris; Henry A Erlich; George S Eisenbarth; Marian Rewers Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Marisa DeGaetani; Christina A Tennyson; Benjamin Lebwohl; Suzanne K Lewis; Hussein Abu Daya; Carolina Arguelles-Grande; Govind Bhagat; Peter H R Green Journal: Am J Gastroenterol Date: 2013-05 Impact factor: 10.864
Authors: Noémi Zádori; Dávid Németh; Levente Frim; Nóra Vörhendi; Lajos Szakó; Szilárd Váncsa; Péter Hegyi; József Czimmer Journal: Int J Gen Med Date: 2022-10-12
Authors: Dolores Gabrieli; Fabiana Ciccone; Annalisa Capannolo; Angelo Viscido; Giorgio Valerii; Donatella Serva; Stefano Necozione; Gino Coletti; Giuseppe Calvisi; Dina Melideo; Giuseppe Frieri; Giovanni Latella Journal: United European Gastroenterol J Date: 2017-01-18 Impact factor: 4.623
Authors: Jonas F Ludvigsson; Carolina Ciacci; Peter Hr Green; Katri Kaukinen; Ilma R Korponay-Szabo; Kalle Kurppa; Joseph A Murray; Knut Erik Aslaksen Lundin; Markku J Maki; Alina Popp; Norelle R Reilly; Alfonso Rodriguez-Herrera; David S Sanders; Detlef Schuppan; Sarah Sleet; Juha Taavela; Kristin Voorhees; Marjorie M Walker; Daniel A Leffler Journal: Gut Date: 2018-02-13 Impact factor: 23.059
Authors: Mohammad Rostami-Nejad; Mohammad Javad Ehsani-Ardakani; Hamid Assadzadeh; Bijan Shahbazkhani; Enzo Ierardi; Giuseppe Losurdo; Homayon Zojaji; Amirhoshang Mohammad Alizadeh; Nosratollah Naderi; Amir Sadeghi; Mohammad Reza Zali Journal: Middle East J Dig Dis Date: 2016-04